Considerations for Start-Up Biotech Company Valuation

The prospect of government regulation, product liability lawsuits, and customer reliance on third-party payers contribute to the complexity of valuing biotech start-ups. In addition, the inherent complexity of biologic drug manufacturing and storage creates secondary risks that must be considered in a valuation.


Comments are closed.

Do NOT follow this link or you will be banned from the site!
%d bloggers like this: